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Aims In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagli-
flozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with
heart failure with reduced ejection fraction.
...................................................................................................................................................................................................
Methods
and results
Health status was assessed by the Kansas City Cardiomyopathy Questionnaires-clinical summary score (KCCQ-
CSS). The influence of baseline KCCQ-CSS (analyzed by tertiles) on the effect of empagliflozin on major outcomes
was examined using Cox proportional hazards models. Responder analyses were performed to assess the odds of
improvement and deterioration in KCCQ scores related to treatment with empagliflozin. Empagliflozin reduced
the primary outcome of cardiovascular death or heart failure hospitalization regardless of baseline KCCQ-CSS ter-
tiles [hazard ratio (HR) 0.83 (0.68–1.02), HR 0.74 (0.58–0.94), and HR 0.61 (0.46–0.82) for <62.5, 62.6–85.4, and
>_85.4 score tertiles, respectively; P-trend = 0.10]. Empagliflozin improved KCCQ-CSS, total symptom score, and
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overall summary score at 3, 8, and 12 months. More patients on empagliflozin had >_5-point [odds ratio (OR) 1.20
(1.05–1.37)], 10-point [OR 1.26 (1.10–1.44)], and 15-point [OR 1.29 (1.12–1.48)] improvement and fewer had >_5-
point [OR 0.75 (0.64–0.87)] deterioration in KCCQ-CSS at 3 months. These benefits were sustained at 8 and
12 months and were similar for other KCCQ domains.
...................................................................................................................................................................................................
Conclusion Empagliflozin improved cardiovascular death or heart failure hospitalization risk across the range of baseline health
status. Empagliflozin improved health status across various domains, and this benefit was sustained during long-
term follow-up.
...................................................................................................................................................................................................
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Introduction
Besides the risk for mortality and recurrent hospitalizations, patients
with heart failure with reduced ejection fraction (HFrEF) also suffer
from impaired health status.1,2 Improvements in physical functioning
and symptoms constitute major treatment goals in these patients as
reflected by the guidance statements from regulatory agencies and
the recognition of Kansas City Cardiomyopathy Questionnaire
(KCCQ) and the Minnesota Living with Heart Failure Questionnaire
by the Food and Drug Administration as a clinical trial endpoint, or
component of a combined endpoint to evaluate devices or drugs for
heart failure.3,4
The sodium glucose co-transporter 2 (SGLT2) inhibitors empagli-
flozin and dapagliflozin have been shown to reduce the composite of
heart failure hospitalizations or cardiovascular mortality.5–8 In the
Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure
(DAPA-HF) trial, dapagliflozin improved cardiovascular outcomes
across the range of baseline KCCQ scores and improved health
status of patients compared with placebo.7 As compared with
DAPA-HF, the EMPEROR-Reduced (Empagliflozin Outcome Trial
in Patients with Chronic Heart Failure with Reduced Ejection
Fraction) trial was designed to be enriched for higher-risk patients
with HFrEF, with lower left ventricular ejection fraction, higher
natriuretic peptide levels, and worse renal function.8 It is important
to assess the benefit of novel therapies on clinically relevant end-
points across the spectrum of disease severity, as has been done
previously with angiotensin-converting enzyme inhibitors, beta-
blockers, and mineralocorticoid receptor antagonists in HFrEF.
Patients with more advanced disease may or may not respond
similarly to those with milder symptoms and functional impairment.
In this secondary analysis of the EMPEROR-Reduced trial, we eval-
uated the effects of health status on the benefits of empagliflozin with
respect to major clinical outcomes as well as the effects of empagliflo-
zin on health status.
Graphical abstract
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Table 1 Baseline characteristics according to Kansas City Cardiomyopathy Questionnaire-clinical summary score
scores at baseline
KCCQ-CSS at baseline P-value
Tertile <62.5
(N 5 1220)
Tertile 62.6–85.4
(N 5 1253)
Tertile 85.4
(N 5 1232)
Age (years) 66.6 (11.4) 67.3 (10.5) 66.7 (11.1) 0.7545
Women 393 (32.2%) 292 (23.3%) 200 (16.2%) <0.0001
Race <0.0001
Asian 104 (8.5%) 209 (16.7%) 348 (28.2%)
Black 112 (9.2%) 79 (6.3%) 66 (5.4%)
White 952 (78.0%) 909 (72.5%) 754 (61.2%)
Other or missing 52 (4.3%) 56 (4.5%) 64 (5.2%)
Geographic region <0.0001
Asia 63 (5.2%) 143 (11.4%) 286 (23.2%)
Europe 472 (38.7%) 488 (38.9%) 384 (31.2%)
North America 140 (11.5%) 147 (11.7%) 137 (11.1%)
Latin America 508 (41.6%) 409 (32.6%) 365 (29.6%)
Others 37 (3.0%) 66 (5.3%) 60 (4.9%)
Systolic blood pressure (mmHg) 121.7 (16.0) 122.3 (15.4) 122.0 (15.5) 0.6425
Diastolic blood pressure (mmHg) 74.0 (11.1) 74.1 (10.4) 73.6 (10.8) 0.3552
Pulse (bpm) 72.4 (11.9) 71.3 (11.9) 70.0 (11.3) <0.0001
Body mass index (kg/m2) 28.8 (5.6) 28.0 (5.4) 26.9 (5.0) <0.0001
Body mass index >_30 (kg/m2) 461 (37.8%) 411 (32.8%) 288 (23.4%) <0.0001
Estimated glomerular filtration rate (mL/min/1.73 m2) 60.8 (21.8) 61.8 (21.4) 63.3 (21.3) 0.0040
Estimated glomerular filtration rate <60 (mL/min/1.73 m2) 605 (49.6%) 623 (49.7%) 559 (45.4%) 0.0379
N-terminal pro B-type natriuretic peptide (pg/mL) 2227 (1280-4274) 1846 (1115-3347) 1679 (993-2912) <0.0001
Ischaemic etiology 631 (51.7%) 674 (53.8%) 615 (49.9%) 0.3677
Left ventricular ejection fraction (%) 27.3 (6.1) 27.4 (5.9) 27.7 (6.0) 0.0600
New York Heart Association class <0.0001
II 670 (54.9%) 990 (79.0%) 1121 (91.0%)
III 532 (43.6%) 263 (21.0%) 109 (8.8%)
IV 18 (1.5%) 0 2 (0.2%)
Hypertension 915 (75.0%) 927 (74.0%) 842 (68.3%) 0.0002
Diabetes 656 (53.8%) 595 (47.5%) 593 (48.1%) 0.0054
Atrial fibrillation 490 (40.2%) 457 (36.5%) 414 (33.6%) 0.0005
Heart failure hospitalization within 12 months 384 (31.5%) 382 (30.5%) 378 (30.7%) 0.6715
Prior myocardial infarction 555 (45.5%) 547 (43.7%) 513 (41.6%) 0.0544
Prior surgical or percutaneous coronary intervention 485 (39.8%) 529 (42.2%) 504 (40.9%) 0.5645
Angiotensin converting enzyme inhibitor 545 (44.7%) 572 (45.7%) 570 (46.3%) 0.4283
Angiotensin receptor blocker 306 (25.1%) 303 (24.2%) 293 (23.8%) 0.4536
Angiotensin receptor neprilysin inhibitor 226 (18.5%) 241 (19.2%) 258 (20.9%) 0.1304
Diuretica 1107 (90.7%) 1099 (87.7%) 1020 (82.8%) <0.0001
Cardiac glycosides 237 (19.4%) 183 (14.6%) 170 (13.8%) 0.0001
Beta-blocker 1156 (94.8%) 1186 (94.7%) 1168 (94.8%) 0.9544
Mineralocorticoid receptor antagonist 896 (73.4%) 889 (70.9%) 855 (69.4%) 0.0272
Anti-platelet 658 (53.9%) 666 (53.2%) 651 (52.8%) 0.5878
Anti-coagulant 490 (40.2%) 493 (39.3%) 465 (37.7%) 0.2191
Statin 826 (67.7%) 872 (69.6%) 836 (67.9%) 0.9390
Implantable cardiac defibrillator 379 (31.1%) 431 (34.4%) 357 (29.0%) 0.2637
Cardiac resynchronization therapy 139 (11.4%) 169 (13.5%) 131 (10.6%) 0.5547
Data are mean (SD), median (interquartile range), or number (%). Race was reported by the patients. Those who identified with more than one race or with no race were clas-
sified as ‘other’. Angiotensin receptor blocker is excluding valsartan when taken with sacubitril because sacubitril/valsartan is shown as angiotensin receptor neprilysin inhibitor.
KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire-clinical summary score.
aExcluding mineralocorticoid receptor antagonists.
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Study design and patient population
The design and primary results of EMPEROR-Reduced have been pub-
lished previously.8,9 Briefly, EMPEROR-Reduced was a randomized,
double-blind, parallel-group, placebo-controlled, event-driven study that
enrolled adult patients who had chronic heart failure with New York
Heart Association (NYHA) functional class II–IV symptoms with a left
ventricular ejection fraction <_40%. To enrol patients at increased risk of
events, the number of patients with an ejection fraction of >30% was lim-
ited by requiring that they had been hospitalized for heart failure within
12 months or had exceptionally high levels of N-terminal pro-hormone
B-type natriuretic peptide (NT-proBNP), i.e. >1000 or >2500 pg/mL in
those with an ejection fraction of 31–35% or 36–40%, respectively. NT-
proBNP level thresholds were doubled in patients with atrial fibrillation.
Key exclusion criteria included symptomatic hypotension or a systolic
blood pressure of <100 mmHg and an estimated glomerular filtration
rate (eGFR) of <20 mL/min/1.73 m2 body surface area or requiring dialy-
sis. The Ethical Committee of each of the 520 sites in 20 countries
approved the protocol, and all patients gave written informed consent.
Quality of life outcome measures
The KCCQ-23 is a 23-item, disease-specific measure that assesses the im-
pact of heart failure on the perspective of patients of their health status.10
The KCCQ-23 has been shown to be valid, reliable, and sensitive to clin-
ical changes, and KCCQ scores are associated with death, hospitalization,
and costs.11,12 The KCCQ-23 was completed via paper-and-pen version
in person by patients at randomization, 3, 8, and 12 months (more specif-
ically, at 12, 32, and 52 weeks) without assistance by site study staff. In the
KCCQ-23, the clinical summary score (CSS) includes the physical func-
tion and symptoms domains; the total symptom score (TSS) quantifies
symptom frequency and severity; and the overall summary score (OSS) is
derived from TSS, physical function, quality of life, and social function.
Scores are transformed to a range of 0–100, where higher scores re-
flect better health status.
Statistical analysis
Patients were categorized into the pre-specified three groups according
to tertiles of baseline KCCQ-CSS: (i) <62.5, (ii) 62.6–85.4, and (iii) >_85.4
points. Baseline characteristics were summarized as means with standard
deviation, medians with interquartile ranges, or frequencies and
Figure 1 Effects of empagliflozin vs. placebo on time to first event of cardiovascular death or heart failure hospitalization according to baseline
Kansas City Cardiomyopathy Questionnaires-clinical summary score tertile. Cumulative incidence curves for empagliflozin vs. placebo demonstrating
time to composite of cardiovascular death or heart failure hospitalization in (A) lowest baseline Kansas City Cardiomyopathy Questionnaires-clinical
summary score tertile, (B) middle baseline Kansas City Cardiomyopathy Questionnaires-clinical summary score tertile, and (C) highest baseline
Kansas City Cardiomyopathy Questionnaires-clinical summary score tertile. CI, confidence interval; HR, hazard ratio.
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..percentages. The rates of primary endpoint of cardiovascular death or
heart failure hospitalization across KCCQ-CSS tertiles were compared
using cumulative incidence curves. Hazard ratios (HRs) with 95% confi-
dence intervals (CIs) and two-sided P-values were calculated using a Cox
proportional hazards model. The pre-specified secondary outcomes
were the occurrence of adjudicated total hospitalizations for heart failure
(including first and recurrent events) and the slope of change in eGFR
during double-blind therapy. These pre-specified secondary outcomes
were also compared across KCCQ categories. For total hospitalizations
for heart failure, a joint frailty model (with cardiovascular death as a com-
peting risk) was used and for slope a random coefficient model was used
based on on-treatment data.8,9 The differences in mean KCCQ-CSS, TSS,
and OSS between empagliflozin and placebo were calculated based on all
observed data (on- or off-treatment) using a mixed model for repeated
measurements. No imputations were made for the occurrence of death.
The least-squares mean differences between treatments were estimated
following adjustment for baseline KCCQ values, age, eGFR, region, dia-
betes status, sex, and left ventricular ejection fraction.9 The adjustment
for left ventricular ejection fraction was based on categories (<_30, >30 to
<_35, and >35%) that reflected the inclusion criteria for the trial.
We performed responder analyses to investigate the proportion of
patients on empagliflozin and placebo who had >_5-, >_10-, and >_15-
point improvement or >_5-point deterioration in KCCQ scores at 3,
8, and 12 months; these thresholds are generally regarded as clinically
meaningful changes.13,14 Odds ratios (ORs) along with 95% CI and
two-sided P-values were calculated using logistic regression models,
which included baseline scores, age, eGFR, region, diabetes status, sex,
and left ventricular ejection fraction. Values for patients who were
lost to follow-up or dropped out before 3, 8, or 12 months were
imputed and estimates were combined using Rubin’s rules. Patients
who died before 3, 8, or 12 months were counted as not improved
in the analysis of improvement and deteriorated in the analysis of de-
terioration. To accommodate for the fact that patients cannot have
KCCQ scores that exceed 100 (the so-called ‘ceiling effect’), patients
with a baseline value of >_95 or >_90 or >_85 points in KCCQ domains
were considered to have 5- or 10- or 15-point improvement if their
values remained >_95 or 90 or 85. Similarly, patients with a KCCQ
....................................................................................................................................................................................................................
Table 2 Effect of empagliflozin on pre-specified outcomes by baseline tertiles of Kansas City Cardiomyopathy
Outcome Empagliflozin Placebo HR (95% CI) P-trend*
Cardiovascular death or heart failure hospitalization
KCCQ-CSS Tertile 1 (<62.5) 173/601 (29%) 200/619 (32%) 0.83 (0.68–1.02) 0.100
KCCQ-CSS Tertile 2 (62.6–85.4) 115/624 (18%) 148/629 (24%) 0.74 (0.58–0.94)
KCCQ-CSS Tertile 3 (>_85.4) 72/628 (12%) 112/604 (19%) 0.61 (0.46–0.82)
KCCQ-TSS Tertile 1 (<66.7) 174/595 (29%) 199/621 (32%) 0.84 (0.69–1.04) 0.065
KCCQ-TSS Tertile 2 (66.8–89.6) 112/623 (18%) 146/622 (24%) 0.73 (0.57–0.94)
KCCQ-TSS Tertile 3 (>_89.6) 74/635 (12%) 115/609 (19%) 0.61 (0.45–0.81)
KCCQ-OSS Tertile 1 (<58.9) 175/597 (29%) 198/623 (32%) 0.85 (0.70–1.05) 0.102
KCCQ-OSS Tertile 2 (59.0–80.7) 114/621 (18%) 157/630 (25%) 0.68 (0.53–0.87)
KCCQ-OSS Tertile 3 (>_80.7) 71/635 (11%) 105/599 (18%) 0.65 (0.48–0.88)
Total number of hospitalizations for heart failure
KCCQ-CSS Tertile 1 (<62.5) 195/601 235/619 0.80 (0.59–1.09) 0.161
KCCQ-CSS Tertile 2 (62.6–85.4) 118/624 188/629 0.65 (0.47–0.91)
KCCQ-CSS Tertile 3 (>_85.4) 75/628 129/604 0.59(0.40–0.85)
KCCQ-TSS Tertile 1 (<66.7) 203/595 230/621 0.89 (0.66–1.21) 0.033
KCCQ-TSS Tertile 2 (66.8–89.6) 114/623 186/621 0.58 (0.42–0.80)
KCCQ-TSS Tertile 3 (>_89.6) 71/635 136/609 0.56 (0.39–0.81)
KCCQ-OSS Tertile 1 (<58.9) 190/597 230/623 0.83 (0.61–1.12) 0.277
KCCQ-OSS Tertile 2 (59.0–80.7) 121/621 199/630 0.60 (0.43–0.83)
KCCQ-OSS Tertile 3 (>_80.7) 77/635 123/599 0.65 (0.45–0.95)
Slope of change in eGFR (mL/min/1.73 m2/year) for empagliflozin and placebo, with difference in slope (SE)
KCCQ-CSS Tertile 1 (<62.5) -1.0 (0.41) -2.2 (0.42) 1.25 (0.59) 0.74
KCCQ-CSS Tertile 2 (62.6–85.4) -0.33 (0.40) -2.6 (0.39) 2.27 (0.56)
KCCQ-CSS Tertile 3 (>_85.4) -0.37 (0.38) -1.9 (0.39) 1.56 (0.54)
KCCQ-TSS Tertile 1 (<66.7) -0.98 (0.41) -2.2 (0.42) 1.25(0.59) 0.54
KCCQ-TSS Tertile 2 (66.8–89.6) -0.42 (0.39) -2.4 (0.40) 2.08 (0.56)
KCCQ-TSS Tertile 3 (>_89.6) -0.29 (0.39) -2.05 (0.39) 1.76 (0.55)
KCCQ-OSS Tertile 1 (<58.9) -0.96 (0.42) -2.2 (0.41) 1.34 (0.59) 0.44
KCCQ-OSS Tertile 2 (59.0–80.7) -0.48 (0.39) -2.3 (0.40) 1.77 (0.56)
KCCQ-OSS Tertile 3 (>_80.7) -0.26 (0.38) -2.2 (0.39) 1.97 (0.55)
CI, confidence interval; CSS, clinical summary score; eGFR, estimated glomerular filtration rate; HR, hazard ratio; KCCQ, Kansas City Cardiomyopathy; OSS, overall summary
score; TSS, total symptom score.
*P-value from trend test assuming ordering of the KCCQ tertiles and testing for a linear trend across subgroups.
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..score at baseline that was <_5 points were defined as deteriorated if
their score remained <_5 points.7 Details about the methods used for
multiple imputation and for correction for the ceiling effect are shown
in Supplementary material online, Appendix S1. All analyses were con-
ducted using SAS version 9.4 (SAS Institute, Cary, NC, USA). A P-
value of <0.05 was considered statistically significant.
Results
Patient population
Baseline characteristics of the patients according to KCCQ-CSS are
shown in Table 1. Overall, the mean KCCQ-CSS was 70.7 (21.9).
Patients with lower KCCQ-CSS results were more often women,
obese, white, enrolled in Latin America, had higher NT-proBNP con-
centrations, and were more likely to have NYHA class III symptoms
and history of diabetes or atrial fibrillation. Left ventricular ejection
fraction, blood pressure, and proportion of patients with implantable
cardioverter defibrillator were similar across the tertiles of KCCQ-
CSS. Supplementary material online, Figure S1 provides an overview
of the availability of KCCQ-CSS data at each time point in this analysis
for the empagliflozin and placebo group. Twenty-five patients (10 on
empagliflozin and 15 on placebo) had missing KCCQ-CSS data at
baseline. In patients who were alive and where the time point of ran-
domization allowed for a 3-, 8-, and 12-month follow-up assessment,
KCCQ-CSS data were available for 3498 (95%), 3201 (93%), and
2472 (92%) patients, respectively. Baseline characteristics for patients
with missing KCCQ-CSS data at baseline are shown in
Supplementary material online, Table S1. Supplementary material on-
line, Figure S2 shows the histogram for KCCQ-CSS at baseline.
Effect of baseline health-related quality
of life on pre-specified primary and
secondary outcomes
The incidence rate per 100 patient years at the risk of composite of
cardiovascular death or heart failure hospitalization was higher in
patients with lower baseline KCCQ-CSS (29.4, 19.8, and 15.0 per
100 patient years at risk on placebo for KCCQ-CSS score <62.5,
62.6–85.4, and >_85.4, respectively). Empagliflozin reduced the pri-
mary outcome of cardiovascular death or heart failure hospitalization
relative to placebo regardless of baseline KCCQ-CSS tertiles [HR
0.83 (0.68–1.02), HR 0.74 (0.58–0.94), and HR 0.61 (0.46–0.82) for
<62.5, 62.6–85.4, and >_85.4 score tertiles, respectively; P-
Figure 2 Effects of empagliflozin vs. placebo on mean Kansas City Cardiomyopathy Questionnaire scores. Changes in (A) Kansas City
Cardiomyopathy Questionnaire-clinical summary score, (B) Kansas City Cardiomyopathy Questionnaire-total symptom score, and (C) Kansas City
Cardiomyopathy Questionnaire-overall summary score from baseline to 3, 8, and 12 months for empagliflozin vs. placebo. All observed data were
used regardless whether on- or off-treatment. Adj. mean diff., adjusted mean difference; CI, confidence interval; CSS, clinical summary score; KCCQ,
Kansas City Cardiomyopathy Questionnaire; OSS, overall summary score; TSS, total symptom score.
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.trend = 0.10] (Figure 1). Results were similar for KCCQ-TSS and
KCCQ-OSS (Supplementary material online, Figures S3 and S4).
Empagliflozin reduced the total number of heart failure hospitaliza-
tions across KCCQ-CSS tertiles [HR 0.80 (0.59–1.09); HR 0.65 (0.47,
0.91); and HR 0.59 (0.40, 0.85) for <62.5, 62.6–85.4, and >_85.4 score
tertiles, respectively; P-trend = 0.16]. Results were similar for KCCQ-
OSS and KCCQ-TSS (Table 2).
The beneficial effect of empagliflozin relative to placebo on the
rate of decline of eGFR was present across all tertiles of KCCQ-CSS
[mean change for empagliflozin vs. placebo: 1.25 (0.59) mL/min/1.73
m2/year for tertile <62.5; 2.27 (0.56) mL/min/1.73 m2/year for tertile
62.6–85.4; and 1.56 (0.54) mL/min/1.73 m2/year for tertile >_85.4; P-
trend = 0.74]. Results were similar for KCCQ-OSS (P-trend = 0.44)
and KCCQ-TSS (P-trend = 0.54) (Table 2).
Effect of empagliflozin on health-related
quality of life outcomes
The mean changes in KCCQ-CSS, KCCQ-TSS and KCCQ-OSS by
treatment arms over time are presented in Figure 2A–C, respectively.
Empagliflozin significantly improved KCCQ-CSS (by 1.94, 1.35, and
1.61 points), TSS (2.52, 1.64, and 1.69 points), and OSS (1.77, 1.30,
and 1.52 points) vs. placebo at 3, 8, and 12 months, respectively
(P < 0.05 for all, Figure 3). The effect of empagliflozin on KCCQ-CSS,
KCCQ-TSS, and KCCQ-OSS by tertiles of baseline score at 3, 8, and
12 months is shown in Table 3.
Responder analysis
The results of the responder analyses are shown in Figure 4. At all
time points, patients in the empagliflozin group were more likely to
show improvement and less likely to experience deterioration in
KCCQ-CSS. At 3 months, the ORs for the effect of empagliflozin vs.
placebo were 1.20 (95% CI 1.05–1.37) for a >_5-point improvement,
1.26 (95% CI 1.10–1.44) for a >_10-point improvement, 1.29 (95% CI
1.12–1.48) for a >_15-point improvement, and 0.75 (95% CI 0.64–
0.87) for a >_5-point deterioration (all P < 0.05). At 8 months, the
ORs for the effect of empagliflozin vs. placebo were 1.20 (95% CI
1.04–1.37) for a >_5-point improvement, 1.21 (95% CI 1.06–1.38) for
a >_10-point improvement, 1.20 (95% CI 1.05–1.38) for a >_15-point
improvement, and 0.85 (95% CI 0.73–0.99) for a >_5-point deterior-
ation (all P < 0.05). A similar pattern was observed at these time
points for KCCQ-TSS and KCCQ-OSS.
Discussion
We report several key findings in this secondary analysis of the
EMPEROR-Reduced trial. First, empagliflozin reduced the primary
outcome of cardiovascular death or heart failure hospitalization
across the range of KCCQ-23 scores. Second, empagliflozin signifi-
cantly improved clinically relevant domains of health status including
the KCCQ-CSS, KCCQ-TSS, and KCCQ-OSS scores; these benefits
were observed at the first post-randomization assessment and were
sustained over the first year of double-blind therapy. Third, using clin-
ically relevant thresholds of a 5-, 10-, or 15-point increase and a 5-
point decline, patients treated with empagliflozin were significantly
Figure 3 Adjusted mean difference in Kansas City Cardiomyopathy Questionnaire-clinical summary score, total symptom score, overall summary
score, and sub-domains for empagliflozin vs. placebo at 3, 8, and 12 months. All observed data were used regardless whether on- or off-treatment. CI,
confidence interval; KCCQ, Kansas City Cardiomyopathy Questionnaire.
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more likely to show improvement and less likely to experience de-
terioration, when compared with placebo. These findings on patient
centred outcomes, when taken together with the benefits of SGLT2
inhibitors to reduce the risk of major heart failure and serious ad-
verse renal events, support a role for SGLT2 inhibitors as a key com-
ponent of foundational therapy for patients with HFrEF.
Previous analyses have raised the possibility that patients with
milder severity of symptoms of heart failure may show a particu-
larly pronounced response to SGLT2 inhibitors.5,8 In the large-
scale DAPA-HF trial, SGLT2 inhibition reduced the risk of cardio-
vascular death or worsening heart failure requiring hospitalization
or urgent care by 37% in patients with class II symptoms, but by
only 10% in patients with class III–IV symptoms.5 The difference in
the magnitude of the benefit on the risk of cardiovascular death
and hospitalization for heart failure between patients with milder
and more severe symptoms was less striking with empagliflozin in
the EMPEROR-Reduced trial, with risk reductions of 29% and 17%
for class II and class III, respectively.8 In the current analysis, as
compared with patients with relatively poor health status, those
with better health status at baseline showed a numerically greater
benefit on the risk of cardiovascular death and hospitalization for
heart failure with empagliflozin. However, in the current trial, nei-
ther NYHA class nor KCCQ health status at baseline exerted a
statistically significant influence on the magnitude of the response
to empagliflozin.8,15 Importantly, even in patients with the worst
KCCQ health status at baseline, the effect of empagliflozin to re-
duce the risk of heart failure hospitalizations and slow the decline
in glomerular filtration rate remained clinically important.
When compared with placebo, empagliflozin improved health sta-
tus as assessed by the KCCQ by 1.5–2.0 points, an effect that was
statistically significant regardless of the KCCQ domain; the effect was
seen at the first double-blind assessment and was sustained for
52 weeks. These results are strikingly similar, both in magnitude and
time course, to the effects of dapagliflozin reported in the DAPA-HF
trial.7 Although changes in KCCQ scores of at least 5 points are often
considered to be clinically meaningful when assessed in individual
patients, this threshold is not applicable to the assessment of
between-group differences in populations of patients, especially
when many patients have reasonably high KCCQ scores at the time
of enrolment in the trial.14 It is therefore, noteworthy that, in trials
with sacubitril/valsartan and ivabradine, meaningful decreases in the
risk of cardiovascular death or hospitalization for heart failure have
generally been accompanied by between-group differences of 1.5–
2.5 points in favor of active treatment.16,17 Nevertheless, if 5- and 10-
point thresholds are applied to the participants in the EMPEROR-
Reduced trial, patients in the empagliflozin groups were 15–20% more
likely to show meaningful improvement and 15–20% less likely to show
meaningful deterioration in health status. These ORs in favor of empagli-
flozin with respect to health status are also similar to those reported
with dapagliflozin in the DAPA-HF trial. However, such cross-trial com-
parisons should be carried out with caution since different trials may
focus on different KCCQ domains and may differ with respect to their
handling of missing data due to patient dropout or death. Furthermore,
it is understood that patients with a reasonably high KCCQ scores at
baseline cannot show an improvement in KCCQ score even if they
were to experience symptomatic benefits, and different trialists often
take different approaches to the analysis of these ceiling effects.
The results of this analysis should be interpreted in light of the fact
that they represent secondary findings and that the KCCQ-23 data
were missing for some patients at baseline and at follow-up.
Moreover, the analysis of KCCQ-23 following randomization did not
take into account the occurrence of deaths since there were more
deaths in patients on placebo, any analysis that imputed for death
would have led to larger estimated treatment effects. Furthermore,
as with other trials, our results may not be generalizable to patients
who did not fulfil the eligibility criteria for participation in the
EMPEROR-Reduced trial.
In conclusion, empagliflozin significantly improved cardiovascular
outcomes across the range of baseline KCCQ-23 domains and
improved health status in patients with HFrEF. Treatment with empa-
gliflozin was accompanied by a higher likelihood of improvement and
a lower likelihood of deterioration in health status. The highly
.................................................................................................
Table 3 Effect of empagliflozin on Kansas City
Cardiomyopathy scores at 3, 8, and 12 months
Placebo-adjusted
mean change
(95% CI)
P-
trend*
3 months
KCCQ-CSS Tertile 1 (<62.5) 2.95 (1.15 to 4.75) 0.215
KCCQ-CSS Tertile 2 (62.6–85.4) 2.05 (0.32 to 3.78)
KCCQ-CSS Tertile 3 (>_85.4) 1.33 (-0.41 to 3.08)
KCCQ-TSS Tertile 1 (<66.7) 4.41 (2.47 to 6.36) 0.036
KCCQ-TSS Tertile 2 (66.8–89.6) 2.62 (0.73 to 4.51)
KCCQ-TSS Tertile 3 (>_89.6) 1.45 (-0.43 to 3.34)
KCCQ-OSS Tertile 1 (<58.9) 2.42 (0.68 to 4.16) 0.205
KCCQ-OSS Tertile 2 (59.0–80.7) 2.64 (0.96 to 4.32)
KCCQ-OSS Tertile 3 (>_80.7) 0.82 (-0.87 to 2.51)
8 months
KCCQ-CSS Tertile 1 (<62.5) 1.32 (-0.64 to 3.28) 0.927
KCCQ-CSS Tertile 2 (62.6–85.4) 1.92 (0.05 to 3.79)
KCCQ-CSS Tertile 3 (>_85.4) 1.18 (-0.70 to 3.06)
KCCQ-TSS Tertile 1 (<66.7) 1.71 (-0.42 to 3.83) 0.613
KCCQ-TSS Tertile 2 (66.8–89.6) 3.06 (1.02 to 5.11)
KCCQ-TSS Tertile 3 (>_89.6) 0.94 (-1.11 to 2.98)
KCCQ-OSS Tertile 1 (<58.9) 1.28 (-0.70 to 3.26) 0.943
KCCQ-OSS Tertile 2 (59.0–80.7) 1.88 (-0.01 to 3.77)
KCCQ-OSS Tertile 3 (>_80.7) 1.33 (-0.57 to 3.23)
12 months
KCCQ-CSS Tertile 1 (<62.5) 1.77 (-0.48 to 4.03) 0.751
KCCQ-CSS Tertile 2 (62.6–85.4) 2.24 (0.09 to 4.39)
KCCQ-CSS Tertile 3 (>_85.4) 1.26 (-0.86 to 3.39)
KCCQ-TSS Tertile 1 (<66.7) 3.03 (0.63 to 5.43) 0.260
KCCQ-TSS Tertile 2 (66.8–89.6) 1.94 (-0.35 to 4.24)
KCCQ-TSS Tertile 3 (>_89.6) 1.03 (-1.25 to 3.31)
KCCQ-OSS Tertile 1 (<58.9) 0.98 (-1.26 to 3.23) 0.733
KCCQ-OSS Tertile 2 (59.0–80.7) 2.65 (0.51 to 4.79)
KCCQ-OSS Tertile 3 (>_80.7) 1.50 (-0.62 to 3.62)
CI, confidence interval; CSS, clinical summary score; KCCQ, Kansas City
Cardiomyopathy; OSS, overall summary score; TSS, total symptom score.
*P-value from trend test assuming ordering of the KCCQ tertiles and testing for
a linear trend across subgroups.
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..concordant findings on patient-reported health status in the
EMPEROR-Reduced and DAPA-HF trials support a role for SGLT2
inhibitors as a part of foundational treatment of HFrEF.
Supplementary material
Supplementary material is available at European Heart Journal online.
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